Drug Profile

ARD 201

Alternative Names: ARD 101+DPP-4 inhibitor; ARD-101 plus DPP-4 inhibitor; ARD-201

Latest Information Update: 27 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aardvark Therapeutics
Class Obesity therapies; Small molecules
Mechanism of Action Dipeptidyl peptidase 4 inhibitors; G protein-coupled receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Suspended Obesity

Most Recent Events

31 Mar 2026 Suspended - Phase-I for Obesity (PO), prior to March 2026
04 Nov 2025 Pharmacodynamics data from a preclinical studies released by Aardvark Therapeutics
12 Aug 2025 Aardvark Therapeutics plans a phase II STRENGTH (Sitagliptin and TAS2R for weight Reduction with Exercise, Nutrition, and GLP-1RA Trial and Hunger assessment) trial for Obesity in the first half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com